17 Capital Partners LLC Purchases Shares of 1,130 IDEXX Laboratories, Inc. $IDXX

Key Points

• 17 Capital Partners LLC has acquired 1,130 shares of IDEXX Laboratories valued at approximately $475,000, as disclosed in their recent SEC filing.
• CEO Jonathan Jay Mazelsky and EVP Sharon E. Underberg sold significant portions of their shares, with Mazelsky selling 29,260 shares and Underberg selling 5,450 shares, indicating a decrease in their positions by 25.99% and 46.96%, respectively.
• IDEXX Laboratories reported earnings of $3.63 per share for the last quarter, exceeding analysts' expectations, and has seen a year-over-year revenue increase of 10.6%.

17 Capital Partners LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,130 shares of the company's stock, valued at approximately $475,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. United Capital Financial Advisors LLC lifted its stake in IDEXX Laboratories by 0.9% during the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after purchasing an additional 22 shares during the last quarter. Sage Mountain Advisors LLC lifted its stake in IDEXX Laboratories by 3.8% during the first quarter. Sage Mountain Advisors LLC now owns 635 shares of the company's stock worth $267,000 after purchasing an additional 23 shares during the last quarter. PDS Planning Inc lifted its stake in IDEXX Laboratories by 3.9% during the first quarter. PDS Planning Inc now owns 641 shares of the company's stock worth $269,000 after purchasing an additional 24 shares during the last quarter. King Luther Capital Management Corp lifted its stake in IDEXX Laboratories by 0.5% during the first quarter. King Luther Capital Management Corp now owns 4,896 shares of the company's stock worth $2,056,000 after purchasing an additional 24 shares during the last quarter. Finally, Gabelli Funds LLC lifted its stake in IDEXX Laboratories by 5.3% during the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after purchasing an additional 25 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDXX traded up $12.6250 during trading hours on Friday, reaching $645.6750. 146,668 shares of the company's stock traded hands, compared to its average volume of 720,535. The firm has a market capitalization of $51.65 billion, a price-to-earnings ratio of 53.72, a P/E/G ratio of 4.14 and a beta of 1.49. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The business's fifty day simple moving average is $567.48 and its two-hundred day simple moving average is $492.73.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating analysts' consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Leerink Partners raised their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. BTIG Research raised their price objective on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Morgan Stanley increased their target price on IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a research report on Friday, August 15th. Finally, JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $550.00 to $675.00 and gave the stock an "overweight" rating in a research report on Monday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $649.44.

Insider Activity

In related news, EVP Nimrata Hunt sold 7,143 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total value of $4,503,161.49. Following the completion of the transaction, the executive vice president owned 18,007 shares in the company, valued at $11,352,153.01. This trade represents a 28.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michael G. Erickson sold 406 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the sale, the executive vice president owned 11,287 shares of the company's stock, valued at $7,336,098.52. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,870 shares of company stock valued at $32,877,757 over the last quarter. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.